Inhibition of Src impairs the growth of met-addicted gastric tumors

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Andrea BertottiLivio Trusolino

Abstract

We examined whether inhibition of Src tyrosine kinase, a downstream effector of the MET oncogene, can hinder the malignant properties of gastric tumors dependent on Met for growth and survival. Sensitivity to Src inhibition was determined in vitro by measuring clonogenic survival (anchorage-independent growth) and in vivo by establishing xenograft models. Four "Met-addicted" gastric carcinoma cell lines (GTL16, MKN45, HS746T, and SNU5) and three Met-independent gastric carcinoma cell lines (KATO III, AGS, and NCI-N87) were treated with the Src inhibitor saracatinib (AZD0530). In GTL16 and KATO III, Src neutralization was also achieved by dasatinib and RNA interference. The biochemical and transcriptional consequences of Src inhibition were explored using anti-phosphoprotein antibodies and oligonucleotide microarrays. Inhibition of Src in Met-addicted gastric carcinoma cell lines (a) decreased the phosphorylation/activation levels of signaling intermediates involved in cell proliferation and protection from apoptosis and down-modulated the expression of several cell cycle regulators; (b) reduced anchorage-independent growth; (c) enhanced impairment of cell viability produced by Met inhibition; and (d) delayed tumorigenesis in xe...Continue Reading

References

Dec 1, 1992·Cancer Genetics and Cytogenetics·G Rege-CambrinG Saglio
Aug 1, 1988·Molecular and Cellular Biology·S GiordanoP M Comoglio
Sep 24, 2004·Cancer Cell·Rumey Ishizawar, Sarah J Parsons
Jun 17, 2005·Cancer Research·Jennifer M GolasFrank Boschelli
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Gromoslaw A SmolenDaniel A Haber
Aug 22, 2006·Current Opinion in Cell Biology·Satyajit K Mitra, David D Schlaepfer
Dec 13, 2006·The Journal of Cell Biology·Andrea BertottiLivio Trusolino
Dec 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Ultan McDermottJeffrey Settleman
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·James BeanWilliam Pao
Feb 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Muhammad EmaduddinStephan M Feller
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistThomas J Lynch
May 31, 2008·Nature Reviews. Drug Discovery·Paolo M ComoglioLivio Trusolino
Jan 20, 2009·Recent Patents on Anti-cancer Drug Discovery·Kwong-Kwok Wong
Apr 28, 2009·Molecular Oncology·Tim P GreenGerard F Costello
May 20, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yi ChenJoyce M Slingerland
Dec 10, 2009·Science Signaling·Andrea BertottiLivio Trusolino
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lucy Gossage, Tim Eisen

❮ Previous
Next ❯

Citations

May 9, 2012·Nature Reviews. Clinical Oncology·Solange Peters, Alex A Adjei
Nov 26, 2010·Nature Reviews. Molecular Cell Biology·Livio TrusolinoPaolo M Comoglio
Jul 26, 2011·Journal of Translational Medicine·Joanna D HolbrookRakesh Kumar
Oct 13, 2014·Molecular Oncology·Viola BigattoCarla Boccaccio
Dec 14, 2011·Trends in Pharmacological Sciences·Siyuan Zhang, Dihua Yu
Sep 17, 2013·Journal of Surgical Oncology·Claus SchildbergH Allgayer
Apr 19, 2011·International Journal of Cancer. Journal International Du Cancer·Davide TortiAndrea Bertotti
Apr 8, 2014·International Journal of Cancer. Journal International Du Cancer·Alessandra GentilePaolo Maria Comoglio
Dec 1, 2011·Therapeutic Advances in Medical Oncology·Shawna Leslie Organ, Ming-Sound Tsao
Jul 26, 2018·Pharmacogenomics·Alessandra RaimondiFilippo Pietrantonio
Feb 1, 2012·Journal of Cancer Research and Clinical Oncology·Stefan HeindlBirgit Luber
Mar 28, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shinji TakaiJohn W Greiner
Aug 16, 2017·Experimental and Therapeutic Medicine·Na SongXiaofang Che
Apr 8, 2020·Updates in Surgery·Rossella ReddavidMaurizio Degiuli
Mar 29, 2012·Molecular Cancer Therapeutics·Giuliana CavalloniFrancesco Leone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis